Pierrel S.p.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
15,651.00
18,122.00
13,533.00
1,136.00
2,516.00
Depreciation, Depletion & Amortization
3,906.00
3,896.00
2,904.00
1,208.00
1,068.00
Other Funds
518.00
263.00
-
3,200.00
4,000.00
Funds from Operations
11,164.00
7,171.00
7,475.00
3,501.00
2,150.00
Changes in Working Capital
1,346.00
642.00
958.00
290.00
3,567.00
Net Operating Cash Flow
9,818.00
7,813.00
8,433.00
3,211.00
1,417.00
Capital Expenditures
1,352.00
2,023.00
1,316.00
547.00
1,102.00
Sale of Fixed Assets & Businesses
12.00
364.00
2,520.00
-
1,196.00
Net Investing Cash Flow
1,360.00
1,701.00
1,004.00
559.00
102.00
Issuance/Reduction of Debt, Net
1,159.00
1,845.00
464.00
1,327.00
1,920.00
Net Financing Cash Flow
13,692.00
10,576.00
5,402.00
2,462.00
2,080.00
Net Change in Cash
2,595.00
1,104.00
2,141.00
1,212.00
742.00
Free Cash Flow
10,110.00
8,704.00
8,934.00
3,593.00
2,428.00
Net Assets from Acquisitions
-
60.00
172.00
100.00
-
Other Sources
234.00
18.00
-
88.00
8.00
Change in Capital Stock
12,015.00
12,158.00
5,866.00
589.00
-
Exchange Rate Effect
81.00
42.00
114.00
96.00
23.00
Other Uses
254.00
-
28.00
-
-

About Pierrel

View Profile
Address
Strada Statale Appia 7-bis 46/48
Capua Caserta 81043
Italy
Employees -
Website http://www.pierrelgroup.com
Updated 09/14/2018
Pierrel SpA engages in the clinical research of medicinal product candidates. It operates through the following business divisions: Tech-driven Contract Research & Development Organization (TCRDO), Contract Manufacturing, and Pharma. The TCRDO division focuses on the repositioning of existing drugs in new indications.